[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361298-105":59,"doc-detail-361298-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinicopathological-factors-associated-with-her2-fish-positivity-in-her2-ihc-2-breast-cancer-a-multicenter-study","Clinicopathological factors associated with HER2 FISH positivity in HER2 IHC 2 + breast cancer - a multicenter study","","Clinicopathological factors linked to HER2 FISH positivity in the clinically challenging HER2 IHC 2+ subgroup were assessed in a multicenter retrospective cohort of 284 patients. FISH positivity occurred in 18.3% (52/284). Compared with FISH-negative cases, FISH-positive tumors showed higher Ki-67, lower PR expression, and a greater proportion of histological grade III. Multivariable analysis identified histological grade III as the sole independent factor associated with FISH positivity, with moderate discriminatory performance (AUC 0.703). Results suggested grade and Ki-67 can provide supportive context but should not replace guideline-recommended confirmatory FISH testing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinicopathological-factors-associated-with-her2-fish-positivity-in-her2-ihc-2-breast-cancer-a-multicenter-study/361298/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinicopathological-factors-associated-with-her2-fish-positivity-in-her2-ihc-2-breast-cancer-a-multicenter-study/361298.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How often were patients with HER2 IHC 2+ found to be FISH-positive in this study?","Question",{"text":112,"@type":113},"Among 284 patients, 52 (18.3%) were FISH-positive.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinicopathological factor was independently associated with HER2 FISH positivity?",{"text":117,"@type":113},"Histological grade III was the only clinicopathological characteristic independently associated with FISH positivity (OR 2.43, 95% CI 1.26–4.71, P = 0.008).",{"name":119,"@type":110,"acceptedAnswer":120},"What associations were observed between FISH-positive status and Ki-67, PR, and tumor grade?",{"text":121,"@type":113},"FISH-positive patients had significantly higher Ki-67 levels, lower PR expression, and a higher proportion of histological grade III tumors compared with FISH-negative patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361298,1790198269,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nClinicopathological factors associated with HER2 FISH positivity in HER2 IHC 2 + breast cancer: a multicenter study  \nWen Yang1,2, Hanqing Deng1, Wenyan Guo1,2, Qiuhong Lan1,2, Guojie Huang1,2, Shiyi Zhang1,2, Shiwen Dong1,2 & WenxinChen1  \nHER2 immunohistochemistry (IHC) 2 + breast cancer represents a clinically challenging subgroup requiring confirmatory fluorescence in situ hybridization (FISH) testing. This multicenter retrospective study included 284 patients with HER2 IHC 2 + breast cancer from a regional cohort to evaluate the FISH positivity rate and identify associated clinicopathological factors. Overall, 52 patients (18.3%) were FISH-positive. Compared with FISH-negative patients, the FISH-positive group showed significantly higher Ki-67 levels, lower PR expression, and a higher proportion of histological grade  \nIII tumors. Multivariable analysis identified histological grade III as the only clinicopathological characteristic independently associated with FISH positivity (OR = 2.43, 95% CI: 1.26–4.71, P = 0.008) . The multivariable model demonstrated moderate discriminatory ability, with an area under the curve of 0.703 (95% CI: 0.628–0.777). Exploratory categorical analysis showed higher FISH positivity rates inpatients with Ki-67 ≥ 30% and histological grade III tumors, with a stepwise increase in FISH positivity according to the number of these risk factors.These findings suggest that histological grade and Ki-67 may provide supportive information for characterizing the likelihood of HER2 gene amplification in HER2 IHC 2 + breast cancer. However, these routinely available clinicopathological features should not replace guideline-recommended confirmatory FISH testing.  \nKeywords Breast cancer, HER2, FISH, HER2 amplification, Ki-67, Histological grade  \nBreast cancer remains the most commonly diagnosed malignancy among women worldwide and a leading cause of cancer-related mortality, accounting for substantial global disease burden1. Molecular classification has become fundamental for guiding individualized treatment strategies, among which human epidermal growth factor receptor 2 (HER2) plays a pivotal role in tumor biology and therapeutic decision-making2. HER2-positive breast cancer, characterized by HER2 protein overexpression and/or HER2 gene amplification, has historically been associated with aggressive clinical behavior; however, the introduction of HER2-targeted therapies has significantly improved survival outcomes3.  \nAccurate determination of HER2 status is therefore essential in clinical practice. Immunohistochemistry (IHC) is widely used as the initial screening method, and cases with an equivocal score of 2 + require confirmation by in situ hybridization (ISH), most commonly fluorescence in situ hybridization (FISH), to assess HER2 gene amplification4,5. According to the updated American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, standardized interpretation criteria have been established to improve diagnostic accuracy and reproducibility5,6. Nevertheless, HER2 IHC 2 + tumors remain a clinically challenging subgroup, because they represent an equivocal category in which final HER2 classification depends on confirmatory ISH results.  \nThe concept of HER2-low breast cancer has emerged as a novel therapeutic category, defined as tumors with IHC 1 + or IHC 2 + and negative ISH results7,8. The pivotal DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan significantly improved progression-free survival and overall survival in patients with HER2-low metastatic breast cancer compared with standard chemotherapy7.These findings have further increased the clinical importance of accurately distinguishing HER2-amplified tumors from non-amplified tumors within the IHC 2 + population7,9.  \n1Department of Breast Surgery, Sanming First Hospital Affiliated to Fujian Medical University, 29","cbCaivGjUb33cxve","https://ap.wps.com/l/cbCaivGjUb33cxve","pdf",1519750,"English","# Background\n## HER2 testing and clinical challenge of IHC 2+\n## HER2-low disease and therapeutic relevance\n# Study aim and rationale\n## Reported variability in FISH positivity rates\n## Clinicopathological factors previously proposed\n## Need for multicenter regional evidence\n# Methods and results\n## Cohort and FISH positivity rate\n## Associations with Ki-67, PR, and histological grade\n## Multivariable analysis and model performance\n## Risk-factor stratification\n# Clinical implications\n## Supportive indicators vs guideline confirmatory testing","[{\"question\":\"How often were patients with HER2 IHC 2+ found to be FISH-positive in this study?\",\"answer\":\"Among 284 patients, 52 (18.3%) were FISH-positive.\"},{\"question\":\"Which clinicopathological factor was independently associated with HER2 FISH positivity?\",\"answer\":\"Histological grade III was the only clinicopathological characteristic independently associated with FISH positivity (OR 2.43, 95% CI 1.26–4.71, P = 0.008).\"},{\"question\":\"What associations were observed between FISH-positive status and Ki-67, PR, and tumor grade?\",\"answer\":\"FISH-positive patients had significantly higher Ki-67 levels, lower PR expression, and a higher proportion of histological grade III tumors compared with FISH-negative patients.\"}]","Clinicopathological factors associated with HER2 FISH positivity in HER2 IHC 2 + breast cancer - a multicenter study | PDF",1790143842,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2d6bb4ae8a3ea1cb9565a12ad3cd877.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0237de5d5fee8fe7d89eb6114cd712d.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7924d5375a8b4c06bd06888b3e301bd2.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6fc96e0e633c87c549088a9eda67093.webp",980,1287]